T6205

AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.

Orexin receptor antagonist 4 is potent and selective orexin 2 receptor (OX2R) antagonist. Orexin receptor antagonist 4 shows IC50 of 4.27 nM and 295 nM for OX2R and OX1R, respectively.

(R)-(+)-Dimethindene maleate is an orally active H1-receptor blocker.

AMPK activator 6 (Compound GC) activates the AMPK pathway and reduces lipid content in HepG2 and 3T3-L1 cells. It significantly suppresses increases in total cholesterol (TC), low-density lipoprotein-C (LDL-C), triglyceride (TG), and other biochemical indices in blood serum, holding research value in non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome.

Lorpucitinib (JNJ-64251330) is an orally available, selective and potent JAK kinase inhibitor for the study of inflammatory and gastrointestinal disorders associated with Janus kinase (JAK) signaling.

D4R antagonist-2 is a potent and selective D4R antagonist (IC50= 6.52 μM) with favorable in vitro pharmacokinetic parameters and good brain penetration, making it a potential research candidate for Parkinson's disease.

NVS-BET-1 is a BET bromodomain inhibitor that can regulate keratinocyte plasticity.

(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent inhibitor of CDK2, JAK2, and FLT3.

Anticancer agent 12 shows cytotoxic activity in malignant cells with no hepatotoxicity.

αβ-Tubulin-IN-1 is a potent, orally active inhibitor of αβ-Tubulin that blocks the cell cycle at the G2/M phase and induces apoptosis. It inhibits tumor cell migration and metastasis, exhibiting significant antitumor efficacy.